Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

68.7K
Overview
68.7K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

970
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
970
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

956
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
956

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamin D3 and Body Composition Association with Graft Function in Long-Term Kidney Transplant Recipients.

International journal of molecular sciences·2026
Same author

Daratumumab as rescue therapy in refractory recurrent FSGS after kidney transplantation: a case series.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report.

Frontiers in immunology·2026
Same author

Decisional preferences and distress among kidney transplant recipients with impaired graft function.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

High Concordance between ddPCR- and NGS-Based Quantification of Donor-Derived Cell-Free DNA Percentage after Kidney Transplantation.

Clinical chemistry·2026
Same author

Improving diagnostic performance of kidney allograft rejection with a model combining relative fraction and absolute copies of donor-derived cell-free DNA-Results from 5 independent cohorts.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026
Same journal

Crystal-Storing Histiocytosis Causing Severe AKI.

Kidney international·2026
Same journal

Peritoneal dialysis in a patient with extensive burn scarring.

Kidney international·2026
Same journal

COPA syndrome unmasked by anti-neutrophil cytoplasmic antibody-positive immune-complex nephritis.

Kidney international·2026
Same journal

Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy.

Kidney international·2026
See all related articles

Related Experiment Video

Updated: Jul 16, 2025

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.5K

A first small step toward personalized immunosuppression.

Klemens Budde1, Lionel Rostaing2

  • 1Department of Nephrology and Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.

Kidney International
|September 22, 2023
PubMed
Summary
This summary is machine-generated.

Individualized tacrolimus dosing, using population pharmacokinetics and pharmacogenetics, offers significant benefits in kidney transplantation. This approach can prevent suboptimal drug exposure and reduce costs, paving the way for precision medicine.

More Related Videos

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

8.8K
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
14:01

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

14.6K

Related Experiment Videos

Last Updated: Jul 16, 2025

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.5K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

8.8K
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
14:01

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

14.6K

Area of Science:

  • Nephrology and immunology
  • Pharmacogenomics and drug metabolism

Background:

  • Tacrolimus is a cornerstone immunosuppressant in kidney transplantation.
  • Current dosing strategies may lead to suboptimal exposure, increasing risks of rejection or toxicity.
  • Individualized dosing holds promise for optimizing outcomes.

Purpose of the Study:

  • To provide evidence supporting an individualized tacrolimus dosing algorithm.
  • To highlight the role of population pharmacokinetics and pharmacogenetics in optimizing tacrolimus therapy.
  • To advocate for the integration of precision medicine principles in kidney transplantation.

Main Methods:

  • Development of a dosing algorithm integrating population pharmacokinetics.
  • Inclusion of pharmacogenetic markers to tailor drug exposure.
  • Assessment of clinical outcomes related to individualized dosing.

Main Results:

  • The proposed algorithm demonstrates potential for improved tacrolimus dosing.
  • Individualized dosing can mitigate risks of both under- and overexposure.
  • Potential for cost savings through optimized drug management.

Conclusions:

  • An individualized tacrolimus dosing algorithm based on pharmacokinetics and pharmacogenetics offers significant benefits.
  • This approach represents a step towards precision medicine in kidney transplantation.
  • Further integration of advanced assessments is crucial for personalized immunosuppressive therapy.